ALDX Aldeyra Therapeutics Inc

$ALDX Doing some dd on this one about the FDRR the chances of this getting approved are very slim, and based on some big DD I feel this gets rejected by the FDA "Reproxalap is an unproven RASP modulator trying to establish a brand-new clinical mechanism." where $OTLK Lytenava is an ophthalmic formulation of bevacizumab (Avastin) and really needed no questions on this already approved drug.

$ALDX I still think traders should stay away till the company supports the SP by insider buying or real news, solid news and no BS about intention.

$ALDX feeling bad for those who held. There is no hope on this company... the CRL was very clear no matter the sugar coating by the company and CEO. I lost alot on this myelf :(

$ALDX IMO will need a miracle for their eye drug to get approved. Glad I sold this piece of shit and basically broke even. Todd is was what I would say “getting high on your own supply”.

$ALDX volume is much lighter today after that 4 million block yesterday. let me see over $1 tomorrow.

$ALDX I hope Todd was on the debate team in college. It’s going to take a performance of a life time to convince the FDA. I got 43k shares ridding on this guy. SMH!

$ALDX Is it really any wonder? Todd has been lying to us for years. Nothing he said was true.

$ALDX More and more looking like a scam, remember CEO is on a million a year of shareholder money and they have produced nothing not even a drug that gets to market, so when you see the CEO buy 100k of shares its like a month's pay and no big deal. Till they do get any positive news this is going down, how far is anyones guess.

$ALDX Near-term catalysts • FDRR submission, the OND meeting, and the decision, all expected in Q4. • The Q3 10-Q in early November: watch cash and any trial starts. • A possible AbbVie decision. AbbVie holds an option on U.S. co-exclusive and ex-U.S. rights to reproxalap, which only matters if reproxalap gets approved.

$ALDX what are the odds that they can get a compromise to an approval, even with limited label? I am not hopeful, but I need wishful thinking 😅

$ALDX $130K at $6? Sold at $5.88. Count my blessings everyday. Down 100k twice.. would’ve been third time, but idk just sold it due to family issues..I can’t imagine having a $13K position..

$ALDX Headed for $1.00 land imo... We got 2 overnight winners already need this one to go... Bounce time.. Ignore the posts that's have nothing to do with this stock.... This is a shame👇👇

$ALDX added back today. this seems to be overdone with catalyst this qtr and funds into 2029. oversold

$ALDX Legal Update FYI: Case #1:26-cv-11510 Docket #34 Massachusetts Federal District Court, Judge Denise Casper Kirby v. Aldeyra Therapeutics, Inc. CLASS ACTION Amended complaint submitted on schedule Oct 9th and is available as pdf for download through PACER federal website for purchase ($3.00). Requested ChatGPT-5 do a legal analysis of the original complaint filed Mar 16, 2026 comparing it to the finalized amended complaint, now 48 pages in length. AI analysis shows the amended complaint is vastly more sophisticated than the early initial allegations and ChatGPT-5 gives it 65-70% favorable odds of surviving/partially surviving a defendant motion for dismissal. Stay tuned...

$ALDX What sh*t stock , $0.50 by the end of the month . Might take another gamble and buy more to bring down my $1.53 holding price

$ALDX what a dog turd this stock and company has become. All they’ve done is burn cash and make zero progress on actually selling any product. Absolute shit show…

$ALDX My prediction is that this company will not remain standalone. When you look at the pipeline, it is too long and too perilous to bring other molecules to market. If the board is doing its job, they must see that. The question will be timing and price. My over/under is 12 months. Price will depend on the outcome of the review (e.g., whether another acute trial is necessary) and the strategy selected.

$ALDX this was just 1.44 few days ago.. this should move up into FDA catalyst. Funds into 2029.

$ALDX FYI - Legal Watch per ChatGPT-5: Stephen G. Machatha, PhD (former CDO ALDX, overseeing clinical trials) is now listed as Senior Vice President, Technical Operations at IMUNON, Inc., providing confirmation that he has secured a new executive role following his departure from Aldeyra. As you recall, he submitted his resignation to ALDX shortly after ALDX received written request from the FDA notifying a need for a PDUFA extension (March 16, 2026) to review ALL clinical trial data, back in December 2025.

$ALDX down a lot on heavy volume is it worth a gamble here under a buck? or is it down for the count